JOHNSON & JOHNSON
JNJ
43 insider filings · Latest: May 1, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Mar 3 9:21 PM | Robert J DeckerVP Corporate Controller | Sale | 4,075 | $247.87 | $1.0M | 23,682(D) | View → |
| Feb 27, 2026 | Feb 27 7:35 PM | Decker Robert J | Proposed Sale | 4,075 | $247.87 | $1.0M | — | View → |
| Feb 20, 2026 | Feb 23 10:20 PM | Timothy SchmidEVP, WW Chair, MedTech | Sale | 1,322 | $245.66 | $324.8K | 25,447(D) | View → |
| Feb 20, 2026 | Feb 20 3:46 PM | Schmid Timothy | Proposed Sale | 1,322 | $245.66 | $324.8K | — | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | James D. SwansonEVP, CIO | Sale | 20,521 | $242.70 | $5.0M | 25,698.131(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | James D. SwansonEVP, CIO | Sale | 41,559 | $243.73 | $10.1M | 25,020.131(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Sale | 89,654 | $242.80 | $21.8M | 14,000(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Sale | 53,931 | $243.00 | $13.1M | 10,658(D) | View → |
| Feb 18, 2026 | Feb 19 2:11 AM | Timothy SchmidEVP, WW Chair, MedTech | Sale | 22,623 | $244.33 | $5.5M | 26,769(D) | View → |
| Feb 17, 2026 | Feb 19 2:11 AM | Vanessa BroadhurstEVP, Global Corp Affairs | Sale | 6,197 | $243.39 | $1.5M | 23,003(D) | View → |
| Feb 18, 2026 | Feb 18 4:14 PM | Schmid Timothy | Proposed Sale | 22,623 | $244.33 | $5.5M | — | View → |
| Feb 17, 2026 | Feb 17 9:10 PM | Broadhurst Vanessa | Proposed Sale | 6,197 | $243.39 | $1.5M | — | View → |
| Feb 17, 2026 | Feb 17 7:52 PM | Swanson James D. | Proposed Sale | 20,521 | $242.70 | $5.0M | — | View → |
| Feb 17, 2026 | Feb 17 7:43 PM | Wolk Joseph J | Proposed Sale | 89,654 | $242.80 | $21.8M | — | View → |
| Feb 17, 2026 | Feb 17 5:44 PM | REED JOHN C | Proposed Sale | 53,931 | $243.00 | $13.1M | — | View → |
| Feb 13, 2026 | Feb 13 7:33 PM | Swanson James D. | Proposed Sale | 41,559 | $243.73 | $10.1M | — | View → |
| Feb 5, 2026 | Feb 5 9:31 PM | Forminard Elizabeth | Proposed Sale | 6,226 | $237.90 | $1.5M | — | View → |
| Jan 26, 2026 | Jan 28 11:07 PM | Joaquin DuatoDirector, CEO and Chairman of the Board | Sale | 100,000 | $221.23 | $22.1M | 30,852(I) | View → |
| Jan 26, 2026 | Jan 26 9:57 PM | Joaquin Duato | Proposed Sale | 100,000 | $220.14 | $22.0M | — | View → |
| Oct 17, 2025 | Oct 17 2:23 PM | REED JOHN C | Proposed Sale | 21,721 | $192.71 | $4.2M | — | View → |
Page 1 of 2
Next →
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Feb 19 2:12 AM | James D. SwansonEVP, CIO | Option Exercise | 51,418 | $165.89 | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Kathryn E WengelEVP, Chief TO and Risk Officer | Grant/Award | 18,162 | $243.45 | 1,217(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Kathryn E WengelEVP, Chief TO and Risk Officer | Option Exercise | 1,241 | — | 1,268(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | Kathryn E WengelEVP, Chief TO and Risk Officer | Option Exercise | 14,357 | — | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Kristen MulhollandEVP, Chief HR Officer | Grant/Award | 21,781 | $243.45 | 1,459(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Kristen MulhollandEVP, Chief HR Officer | Option Exercise | 994 | — | 1,150(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | Kristen MulhollandEVP, Chief HR Officer | Option Exercise | 4,012 | — | 0(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Option Exercise | 64,693 | $131.94 | 33,000(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Option Exercise | 3,849 | — | 3,754(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Grant/Award | 57,656 | $243.45 | 3,863(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | Joseph J WolkExec VP, CFO | Option Exercise | 39,242 | — | 0(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Robert J DeckerVP Corporate Controller | Option Exercise | 683 | — | 687(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | Robert J DeckerVP Corporate Controller | Grant/Award | 5,571 | $243.45 | 700(D) | View → |
| Feb 13, 2026 | Feb 19 2:12 AM | Robert J DeckerVP Corporate Controller | Option Exercise | 3,053 | — | 0(D) | View → |
| Feb 17, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Option Exercise | 51,648 | $157.92 | 59,854(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Grant/Award | 52,928 | $243.45 | 3,546(D) | View → |
| Feb 15, 2026 | Feb 19 2:12 AM | REED JOHN CEVP, Innovative Medicine, R&D | Option Exercise | 3,196 | — | 3,692(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Grant/Award | 29,020 | $243.45 | 1,944(D) | View → |
| Feb 15, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Option Exercise | 2,024 | — | 2,126(D) | View → |
| Feb 13, 2026 | Feb 19 2:11 AM | Elizabeth ForminardEVP, Chief Legal Officer | Option Exercise | 14,357 | — | 0(D) | View → |